Femasys Inc. (FEMY)
NASDAQ: FEMY · Real-Time Price · USD
1.015
+0.024 (2.45%)
Nov 26, 2025, 9:36 AM EST - Market open
Femasys Revenue
Femasys had revenue of $729.39K in the quarter ending September 30, 2025, with 31.44% growth. This brings the company's revenue in the last twelve months to $2.06M, up 63.53% year-over-year. In the year 2024, Femasys had annual revenue of $1.63M with 51.97% growth.
Revenue (ttm)
$2.06M
Revenue Growth
+63.53%
P/S Ratio
14.18
Revenue / Employee
$29,035
Employees
71
Market Cap
59.24M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.63M | 557.14K | 51.97% |
| Dec 31, 2023 | 1.07M | -134.25K | -11.13% |
| Dec 31, 2022 | 1.21M | 26.53K | 2.25% |
| Dec 31, 2021 | 1.18M | 141.77K | 13.66% |
| Dec 31, 2020 | 1.04M | 108.85K | 11.72% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
FEMY News
- 1 day ago - PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment - Business Wire
- 23 days ago - Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million - GlobeNewsWire
- 5 weeks ago - Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo - GlobeNewsWire
- 2 months ago - Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed® - GlobeNewsWire
- 2 months ago - Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand - GlobeNewsWire
- 3 months ago - Femasys Announces Pricing of $8.0 Million Underwritten Public Offering - GlobeNewsWire
- 3 months ago - Femasys Revenue Jumps 85 Percent in Q2 - The Motley Fool
- 3 months ago - Femasys Announces Second Quarter Financial Results for 2025 - GlobeNewsWire